Concepedia

Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma

Manisha Bhutani, David Foureau, Qing Zhang, Myra Robinson, Adina Wynn, Nury Steuerwald, Lawrence J. Druhan, Fei Guo, Katherine Rigby, Mitchell Turner,

Biology of Blood and Marrow Transplantation · 2018 · 22 citations · 22 references

DOIFull text

Open access

Concepts

Abstract

groups. These data support exploration of immune profiling in prospective clinical trials according to MRD-defined responses to identify patients that may benefit from maintenance intensification/modification or maintenance withdrawal.

References

22

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

Meletios Α. Dimopoulos, Albert Oriol, Hareth Nahi et al. · New England Journal of Medicine · 2016 · 1.4K citations · Full text

, , +16

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

Jacques J. M. van Dongen, Ludovic Lhermitte, Sebastian Böttcher et al. · Leukemia · 2012 · 915 citations · Full text

, , +15

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

Don M. Benson, Courtney E. Bakan, Anjali Mishra et al. · Blood · 2010 · 801 citations · Full text

, , +17

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Tineke Casneuf, Xu Steven Xu, Homer Adams et al. · Blood Advances · 2017 · 224 citations · Full text

, , +16

Myeloid-Derived Suppressor Cells Regulate Growth of Multiple Myeloma by Inhibiting T Cells in Bone Marrow

Indu Ramachandran, Anna Martner, Alexandra Pisklakova et al. · The Journal of Immunology · 2013 · 206 citations · Full text

, , +15